TechConnect Innovation Program

Novel LKB1-AMPK Activator for Therapeutic Use in Polycystic Kidney Disease

University of Kansas, KS, United States

TECHNOLOGY SUMMARY

The invention consists of a novel compound and method for treating Polycystic Kidney Disease utilizing a novel liver kinase B1 (LKB1) activator to stimulate AMP-activated protein kinase (AMPK), leading to inhibition of mTOR-mediated cellular proliferation and chloride-dependent fluid secretion, key components of cyst growth.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

FIGURES OF MERIT

Value Proposition: Unique composition of matter patent application.

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Showcase Booth #: 13M

Website: www.kuic.ku.edu

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date:

Primary Sources of Funding: University

Looking for: Both Funding and Development Partners